摘要
One of the challenges of research in myopia is the multifaceted nature of the field. One might think that 30 years after the classic experiments by Wiesel and Raviola,1 which established (or perhaps reestablished to some) the plasticity of eye growth, or some 20 years after the first lens experiments demonstrated the visual control of eye growth in the chick,2 that myopia would be well understood— or at least understood well enough that the visual control of eye growth could be harnessed to provide efficacious clinical treatments. Unfortunately, the fact of visual control has not translated into clear-cut regulation of that controller and has not led to any simple therapy to reduce the risk of onset or to slow the rate of progression. Not that research has been stagnant by any stretch of the imagination. The last decades of research have revealed roles for numerous ocular tissues in the transmission of visual signals modulating eye growth: amacrine cells, retinal pigment epithelium, choroid, and the sclera. The parameters of the visual stimulus regulating eye growth are better understood in terms of spatial frequency, contrast, and temporal frequency. We also now understand that both the central and the peripheral retina are capable of responding to these signals. The fascinating non-linear dynamics of both the exposure to defocus and the ocular response to defocus have also been described, namely the capability of the eye for induction of myopic growth in a short period of time alongside the striking power of brief exposures to “stop” signals to override that growth to restore a normal refractive error. Perhaps the most active area of research has been the biochemistry of ocular growth. The array of compounds that modulate ocular growth is truly staggering despite the fact that none, with the possible exception of atropine, are either available or widely used to treat myopia. This multifaceted challenge made the 13th International Myopia Conference held in Tübingen, Germany, all the more satisfying. Triskaidekaphobia aside, attendees could consider themselves fortunate as the diversity of the program made it the most comprehensive meeting ever held in myopia. Seventeen symposia over 4 days spanned topics such as pathology, imaging, epidemiology, proteomics, and the nature of visual signals during their cascade from retina to sclera. In this issue of Optometry and Vision Science (OVS), Siegwart and Norton3 discuss how myopia might be the result of the loss of sensitivity to the inhibitory effects of myopic visual signals during genetically programmed eye growth. Followers of the meetings will recall that the responsiveness of the retinal periphery to visual manipulations and the protective effect of time outdoors were the major topics from 2008. In addition to progress on these themes, a third highlight of the meeting was the report of genome-wide association studies in myopia from unbelievably large discovery and replication samples following an equally unbelievably large cooperative effort on the part of the study authors. Results were published shortly after the meeting in September in Nature Genetics.4,5 The scope of the work was unprecedented. Thousands of subjects were genotyped, representing participation in seven different eye-related studies. The density of the genotyping was also newsworthy. Whenever one might be tempted to think that progress in myopia research has been slow, consider that the number of markers that constituted genome-wide scanning has grown in about 5 years from under 1,000 to over 1,000,000. The particular strength of these two reports in Nature Genetics (papers in Tübingen by Hysi et al. and Klaver et al. with abstracts in the IMC Symposium Summaries paper in this OVS issue)6 is that the finding from one discovery sample was replicated in a separate sample. Single nucleotide polymorphisms on 15q25 and 15q14 were associated with refractive error. The authors cited RASGRF1 as a potential candidate gene for 15q25 and GJD2 for 15q14 because of their involvement in the transmission and processing of visual signals. In addition, ACTC1 was suggested for 15q14 (encodes smooth muscle actin cardiac muscle alpha actin 1) because it contributes to extracellular matrix remodeling that may be important to myopic growth. Despite the high degree of significance, the impact of these variations was small, with low odds ratios for being homozygous for the risk alleles, and only a small amount of variance in myopia accounted for by these polymorphisms.4,5 The role of the retinal periphery has grown with this meeting, from a hypothetical in Cambridge in 2004 to reports in 2010 from the first clinical trials designed to reduce myopia progression by altering peripheral retinal defocus. The reports were truly international with countries such as Spain, Hong Kong, and Australia represented. Results were generally positive, but the magnitude of the effects were small, typically on the order of about 0.2 mm less growth in axial length or under 0.50 D less progression in treated subjects compared with controls after 12 to 18 months (as an example, see Sankaridurg et al.7). Optimization of lens design and conducting trials for longer periods of time were both strong goals for future research. In this issue of OVS, Tabernero et al.8 present data on peripheral defocus profiles in subjects using a new instrument designed to assess peripheral refraction more rapidly and with a greater density in retinal field angle than previously possible. Interest in the protective effects of time outdoors continued in Tübingen. One of the stronger theories based on evidence from animal studies is that the increased intensity of light outdoors exerts an inhibitory effect on ocular growth. Ashby et al. presented evidence that a light-induced retinal dopamine release may be the mechanism behind this effect.6 Neitz and Neitz presented an intriguing theory that the more predominantly blue spectral composition of light outdoors, in conjunction with variation in retinal cone opsin genes, could influence refractive error.6 Several papers in this issue of OVS address the effect of time outdoors. An alternate theory for the effect of time outdoors is that increased levels of vitamin D may be protective. Mutti and Marks9 present data that myopes have lower blood levels of vitamin D compared with emmetropes. In an interesting contrast, Deng and Gwiazda10 show that infants born during months with more hours of daylight have less hyperopic refractive errors than infants born at other times of year. Finally, Charman11 discusses how visual signals from accommodation, oblique astigmatism, and the relative viewing distances for near vision for reading and for far vision outdoors may influence refractive development. The next International Myopia Conference will be held in California in the San Francisco Bay Area in 2012. What are the challenges that remain in this complex field? Genetic influence is clearly strong but the variance that can be attributed to genetic loci to date is weak. The technology to conduct molecular genetics studies has never been better, but the number of genes that are important to myopia, how they function individually, or how they interact collectively to influence refractive error has not yet been described. Progress in understanding gene-gene interactions or gene networks seems needed. The visual control of eye growth is well accepted, and visually based interventions such as bifocals or alteration of peripheral defocus clearly influence refractive development, but their effects are small; it has not been determined that their benefit accrues consistently over time nor have the specifics of the peripheral visual signal that are influential been determined. This understanding seems a prerequisite to optimized optical treatments. Despite the array of important biochemical agents that modulate eye growth, and patents for same, there were no reports from clinical trials of any new antimyopia pharmaceuticals at this meeting. Perhaps the regulatory climate in the United States discourages progress in this area, but such progress is sorely needed considering the small magnitude of effects from optical therapies. Pharmaceutical interventions, at least hypothetically, continue to have more potential. The protective influence of time outdoors is also well established, but the mechanism for this effect and how best to translate it into therapy safely has not been described. The known damaging effects of light to the skin and the eye cannot be part of any tradeoff for less myopia. The modern era of myopia research is only 30 years old. The 2 years to the next International Myopia Conference feel as if they will pass in the blink of an eye.Figure: From left to right: Donald O. Mutti, OD, PhD, FAAO; Frank Schaeffel, Dr Rer Nat; Marita Feldkaemper, Dr Rer Nat.Donald O. Mutti, OD, PhD, FAAO Columbus, Ohio Frank Schaeffel, Dr Rer Nat Tübingen, Germany Marita Feldkaemper, Dr Rer Nat Tübingen, Germany